Beyin omurilik sıvısı biyoişaretleyici düzeylerinin alzheimer hastalığı'nın klinik gidişat ve prognozu ile ilişkisi
Thesis Type: Expertise In Medicine
Institution Of The Thesis: Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , Turkey
Approval Date: 2022
Thesis Language: Turkish
Student: ÇAĞRI ULUKAN
Supervisor: Başar Bilgiç
Open Archive Collection: AVESIS Open Access Collection
Abstract:Aim: The cerebrospinal fluid (CSF) biomarker profile of Alzheimer's disease's (AD) includes decreased amyloid-β 42, increased tau (tTau) and phosphorylated form of tau, threonine 181 (pTau). The goal of this study was to evaluate the effects of CSF biomarkers on the clinical characteristics and progression of the patients. Methods: The cases whose CSF biomarkers were studied with a prediagnosis of cognitive impairment at Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders outpatient clinic between 2016-2021 were evaluated retrospectively. The CSF biomarker profiles, diagnoses, Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scores, as well as the demographic data of the cases, were recorded at the 6th month, 1st year and 2nd year following admission. According to CSF biomarker levels, groups were divided into quartiles and progression data were compared. Results: Of the 343 people included in the study, 176 (51.3%) were female with a mean age of 62.45 ± 10.42 years. Of these people, 147 (42.9%) were diagnosed with AD patients. A total of 82 (55.71%) AD patients were classified as typical and 65 (44.29%) as atypical. High tTau levels were detected in 5.48% of patients with AD as well as acute dementias such as Creutzfeldt-Jakob disease (CJD). The pTau/tTau ratio had a discriminatory power of 94% when applied to distinguish between CJD and AD. The decrease in the tTau level strongly correlated with the 2-year MMSE change in the whole sample of CSF biomarkers. In the case of AD, only pTau was positively correlated with the change in the CDR score at the 2nd year follow-up. Conclusion: There were no difference in CSF biomarker profiles between typical and atypical AD patients in this study. It has been shown that CSF biomarker levels are effective on the clinical course, and this effect can be detected as early as the 6th month in more than one progression marker. CSF biomarker levels can provide information in estimating the clinical course as well as the diagnosis.